TempraMed

Company Overview

Snapshot

Founded in October 2014 by Ron Nagar and Elina Nagar, TempraMed operates with 11–50 employees. The company has raised a total of $10.18M across 6 funding rounds. In October 2025, TempraMed became publicly listed on the Canadian Securities Exchange.

Business overview

TempraMed is a Health Tech & Life Sciences company focused on developing patent-protected technology for temperature-controlled storage, carrying, and tracking of medication. Its core technology combines ultrahigh vacuum thermal insulation with phase change materials to provide power-free temperature control for extended periods. The company primarily serves the medical devices industry, targeting patients, healthcare providers, and payors with products designed for temperature-sensitive injectable medications like insulin and EpiPens. TempraMed operates in the Medical Treatment & Therapeutics sector, offering solutions that ensure medication potency and track usage.

Strategic signal

TempraMed is rapidly expanding its global reach and strategic partnerships, as evidenced by multiple distribution agreements and intellectual property advancements in the first half of 2026. This includes an expanded strategic partnership with McKesson Medical-Surgical for North American distribution, an exclusive distribution agreement in Brazil, and new LOIs for distribution in Panama. These developments signal a strong commercialization push and increasing market adoption for TempraMed's temperature-controlled medication solutions, positioning the company for significant growth in key international markets.

Company Intelligence Q&A

What was a significant recent commercial expansion for TempraMed?

In June 2026, TempraMed expanded its strategic partnership with McKesson Medical-Surgical to accelerate North American growth and launch its full portfolio across B2B channels, indicating a major push into the institutional healthcare network.

What recent intellectual property milestone did TempraMed achieve?

In May 2026, TempraMed announced a granted Indian Design Patent for its VIVI Cap Smart Product, further strengthening its global intellectual property portfolio.

What was a key strategic partnership for TempraMed in the Israeli market?

In July 2026, TempraMed expanded its institutional healthcare network by partnering with Meuhedet Health Services, a leading HMO in Israel covering over 1 million lives.

What new product did TempraMed launch in early 2026?

In January 2026, TempraMed launched its new product "VIVI Med," designed to unlock new growth opportunities in high-value biologics and injectable medications.

When did TempraMed become a publicly traded company?

TempraMed became public on the Canadian Securities Exchange (CSE) in October 2025.